TARGET Study: Not Quite A Bull’s-Eye For COX-2 Inhibitors Over NSAIDs
This article was originally published in The Tan Sheet
Executive Summary
Novartis' TARGET study found that the COX-2 inhibitor lumiracoxib has approximately one-third the rate of gastrointestinal side effects compared to prescription doses of non-steroidal anti-inflammatory drugs
You may also be interested in...
NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx
OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts
NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx
OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts
NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx
OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts